NL-OMON38805已完成不适用
A Prospective, Nonrandomized, Noninterventional Study to Compare Nexfin CO-trek Cardiac Output with Thermodilution Cardiac Output - Nexfin/TD Clinical Study
Edwards Lifesciences BMEYE0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Subjects will be included if they meet the following criteria:
- •1. Subjects must be at least 18 years of age
- •2. Subjects must give signed written informed consent
- •3. Subjects* height and weight must be accurately obtained prior to study start.
排除标准
- •Subjects will be excluded if any of these items exist:
- •1. Aortic or tricuspid valve regurgitation
- •2. Aortic stenosis or aneurysms
- •3. History of uncontrolled cardiac arrhythmia
- •4. Any peripheral vascular disease or conditions such as Raynaud*s disease or Buerger*s disease
- •5. Insufficient perfusion of the digits
- •6. Inability to place the finger cuff appropriately due to subject anatomy or condition
- •7. Known pregnancy
- •8. Patients being treated with an intra-aortic balloon pump
- •9. Patient is currently participating in an investigational drug or another device study that clinically interferes with the study endpoints
研究者
相似试验
招募中
不适用
Impact of mental health and stress on Physical Recovery of Patients after Total Joint ReplacementCTRI/2022/03/041238Self funded Mrs Shilpi Singh
尚未招募
4 期
A post marketing surveillance study of Moxifloxacin Hydrochloride solution to check its ability to prevent the growth or spread of bacteria & its safety in patient undergoing ophthalmic surgery.CTRI/2023/12/060575ovartis Healthcare Private Limited
招募中
Unknown
A study to see the prevalence of HER2 low, clinical characteristics, treatment patterns, and outcomes in patients with HER2 negative locally advanced or metastatic breast cancer who progressed on systemic anticancer therapy.CTRI/2024/03/063553AstraZeneca Pharma India Ltd
进行中（未招募）
1 期
A prospective, non-randomized, non-controlled, open label, multicenter phase II Study: PTK 787/ ZK222584 in patients with advanced neuroendocrine tumors. - not availableEUCTR2004-002420-18-DEProf. B. Wiedenmann, Klinik für Gastroenterologie, Charité, Campus Virchow54
进行中（未招募）
不适用
A prospective, non-randomised, non-controlled, open label, multicentre phase II study: PTK 787/ZK222584 in patients with advanced neuroendocrine tumours - PTK878/ZK 222584 in patients with advanced NETeuroendocrine TumourEUCTR2004-002420-18-GBCHARITE Universitätsmedizin Berlin Campus Virchow-Klinikum35